Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov;103(7):e485-e495.
doi: 10.1111/aos.17535. Epub 2025 Jun 10.

Consensus-based recommendations for indications and procedures in retinal laser treatment of Telangiectatic capillaries (TelCaps) in vascular macular oedema: A Delphi study

Marie-Noëlle Delyfer  1   2   3 , Jean-François Girmens  3   4 , Corinne Dot  5   6 , Mohamed Bennani  7 , Marie-Benedicte Rougier  2 , Stéphanie Baillif  8 , Pascale Massin  9   10   11 , Vincent Gualino  10   12   13 , Michel Paques  3   4 , Bénédicte Dupas  3   9   10
Affiliations

Consensus-based recommendations for indications and procedures in retinal laser treatment of Telangiectatic capillaries (TelCaps) in vascular macular oedema: A Delphi study

Marie-Noëlle Delyfer et al. Acta Ophthalmol. 2025 Nov.

Abstract

Purpose: The identification of telangiectatic capillaries (TelCaps) in chronic macular oedema (ME) resistant to conventional intravitreal injections (IVIs) has renewed interest in focal laser treatment. However, the indications and modalities of this laser treatment remain to be clarified.

Methods: A modified Delphi approach was used to establish a consensus among French macular laser specialists regarding recommendations on assessment of TelCaps, indications for laser treatment, treatment procedures and follow-up.

Results: Presence of TelCaps should be considered in cases of recurrent vascular oedema that do not respond, or partially respond, to IVIs. A strong consensus has emerged on treating TelCaps with laser when they are located ≥1000 μm from the fovea and associated with thickening of the surrounding retina, usually in combination with IVIs. For TelCaps located <1000 μm from the centre, IVIs alone were preferred. ICG-guided laser treatment was advised to target TelCaps but was not considered mandatory if TelCaps were visible on fundus photography or OCT. Assessment of the effectiveness of laser treatment should be based on reduction in macular thickness on OCT after 3 months, before a second laser session may be considered. Although experts have recommended the use of small, short-duration impacts allowing greying of the lesion, no consensus has been reached on the optimal numerical parameters for the laser procedure.

Conclusion: This study provides precise guidelines on laser treatment for vascular ME in cases of TelCaps, and emphasizes the need for standardized lesion selection and laser parameters to ensure safe and effective ME management.

Keywords: Delphi consensus macular oedema; TelCaps; diabetic retinopathy; focal laser photocoagulation; retinal vein occlusion; telangiectatic capillaries.

PubMed Disclaimer

Conflict of interest statement

MN Delyfer: AbbVie, Bayer, Horus Pharma, Novartis, Roche, Thea. JF Girmens: AbbVie, Bayer, Biogen, Novartis, Roche, Teva, Tilak Healthcare. C Dot: AbbVie, Bayer, Horus Pharma, Novartis, Roche. M Bennani: None. MB Rougier: Abbvie, Bayer, Chiesi, Horus Pharma, Novartis. S Baillif: Abbvie, Alcon, Bausch and Lomb, Bayer, Biogen, Horus Pharma, Novartis, Roche. P Massin: Abbvie, Bayer, Novartis, Roche. V Gualino: Abbvie, Alcon, Bausch and Lomb, Bayer, Novartis, Roche. M Paques: SharpEye. B Dupas: Bayer, Novartis.

Figures

FIGURE 1
FIGURE 1
Modified DELPHI procedure used in this study.
FIGURE 2
FIGURE 2
Composition of the rating group and response rate.
See this image and copyright information in PMC

References

    1. AAO Preferred Practice Pattern (PPP) Retina/Vitreous Panel, Hoskins Center for Quality Eye Care . (2023) Retina Summary Benchmarks. https://www.aao.org/education/summary‐benchmark‐detail/retina‐summary‐be...
    1. Allingham, M.J. , Mukherjee, D. , Lally, E.B. , Rabbani, H. , Mettu, P.S. , Cousins, S.W. et al. (2017) A quantitative approach to predict differential effects of anti‐VEGF treatment on diffuse and focal leakage in patients with diabetic macular edema: a pilot study. Translational Vision Science & Technology, 6, 7. - PMC - PubMed
    1. Avitabile, T. , Azzolini, C. , Bandello, F. , Boscia, F. , de Falco, S. , Fornasari, D. et al. (2017) Aflibercept in the treatment of diabetic macular edema: a review and consensus paper. European Journal of Ophthalmology, 27, 627–639. - PubMed
    1. Baker, C.W. , Glassman, A.R. , Beaulieu, W.T. , Antoszyk, A.N. , Browning, D.J. , Chalam, K.V. et al. (2019) Effect of initial management with Aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the Center of the Macula and Good Visual Acuity: a randomized clinical trial. JAMA, 321, 1880–1894. - PMC - PubMed
    1. Blindbaek, S.L. , Peto, T. & Grauslund, J. (2019) How do we evaluate the role of focal/grid photocoagulation in the treatment of diabetic macular edema? Acta Ophthalmologica, 97, 339–346. - PubMed

MeSH terms

LinkOut - more resources